- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Asthma
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 309KB)
Dupilumab – March 2024
Dupilumab: Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent®
Last updated
30 May 2025